Overall, rising unit sales-as a result of an increasing patient pool-and the uptake of premium-priced products will spur revenue growth in the US vascular access device market.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for vascular access devices in the US across a 10-year period.
Questions Answered in This Report:
The risk of catheter-related BSIs is a prominent issue when it comes to the use of vascular access devices, and reducing this risk will continue to be a focus of health care facilities and manufacturers.
- Can device design and materials minimize infection rates?
- How will uptake of devices with antimicrobial coatings impact the vascular access market?
Vascular access patients are at risk of developing clots, leading to incidence of DVT and venous obstruction.
- How will clinical trials regarding the incidence of DVT among vascular access patients impact the market?
- How will antithrombogenic devices impact the markets for PICCs, CVCs, implantable ports, and dialysis catheters?
Power-injectable PICCs, CVCs, and implantable ports enable physicians to inject the contrast media required for CT scans, thereby reducing the need for additional catheters.
- To what extent will power-injectable PICCs, implantable ports, and Huber needles be adopted and how will this affect unit sales and revenues in their respective markets?
- What effects are power-injectable devices having on the CVC market?